Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

portfolio company news
Written By Guest User

NEW YORK – October 23, 2023 – Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.

Guest User
Previous

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
Next

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023